Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
−0.97 EUR
−15.37 M EUR
3.00 M EUR
6.45 M
About Marker Therapeutics, Inc.
Sector
Industry
CEO
Juan F. Vera
Website
Headquarters
Houston
Founded
1991
FIGI
BBG000GQF329
Marker Therapeutics, Inc. is a clinical-stage immuno-oncology company, which engages in the development and commercialization of novel cell-based immunotherapies and peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications. The company was founded on October 22, 1991 and is headquartered in Houston, TX.
An aggregate view of professional's ratings.
Displays a symbol's price movements over previous years to identify recurring trends.
Frequently Asked Questions
The current price of GX1 is 2.92 EUR — it has decreased by −4.70% in the past 24 hours. Watch MARKER THERAPEUTICS INC stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on GETTEX exchange MARKER THERAPEUTICS INC stocks are traded under the ticker GX1.
GX1 stock has fallen by −14.97% compared to the previous week, the month change is a −11.80% fall, over the last year MARKER THERAPEUTICS INC has showed a 34.07% increase.
We've gathered analysts' opinions on MARKER THERAPEUTICS INC future price: according to them, GX1 price has a max estimate of 17.49 EUR and a min estimate of 17.49 EUR. Watch GX1 chart and read a more detailed MARKER THERAPEUTICS INC stock forecast: see what analysts think of MARKER THERAPEUTICS INC and suggest that you do with its stocks.
GX1 stock is 11.45% volatile and has beta coefficient of 2.32. Track MARKER THERAPEUTICS INC stock price on the chart and check out the list of the most volatile stocks — is MARKER THERAPEUTICS INC there?
Today MARKER THERAPEUTICS INC has the market capitalization of 25.15 M, it has decreased by −3.25% over the last week.
Yes, you can track MARKER THERAPEUTICS INC financials in yearly and quarterly reports right on TradingView.
MARKER THERAPEUTICS INC is going to release the next earnings report on Mar 13, 2025. Keep track of upcoming events with our Earnings Calendar.
GX1 earnings for the last quarter are −0.23 EUR per share, whereas the estimation was −0.35 EUR resulting in a 33.33% surprise. The estimated earnings for the next quarter are −0.27 EUR per share. See more details about MARKER THERAPEUTICS INC earnings.
MARKER THERAPEUTICS INC revenue for the last quarter amounts to 1.73 M EUR, despite the estimated figure of 898.14 K EUR. In the next quarter, revenue is expected to reach 954.80 K EUR.
GX1 net income for the last quarter is −2.07 M EUR, while the quarter before that showed −2.05 M EUR of net income which accounts for −1.27% change. Track more MARKER THERAPEUTICS INC financial stats to get the full picture.
No, GX1 doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Nov 22, 2024, the company has 8.00 employees. See our rating of the largest employees — is MARKER THERAPEUTICS INC on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. MARKER THERAPEUTICS INC EBITDA is −9.16 M EUR, and current EBITDA margin is −440.37%. See more stats in MARKER THERAPEUTICS INC financial statements.
Like other stocks, GX1 shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade MARKER THERAPEUTICS INC stock right from TradingView charts — choose your broker and connect to your account.